{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:15:14Z","timestamp":1779894914222,"version":"3.53.1"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T00:00:00Z","timestamp":1536883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA107399"],"award-info":[{"award-number":["P50 CA107399"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["P01CA044991"],"award-info":[{"award-number":["P01CA044991"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["K24CA184039"],"award-info":[{"award-number":["K24CA184039"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We sought to develop a safe and effective outpatient salvage regimen by replacing ifosfamide within the (R)<jats:styled-content style=\"fixed-case\">ICE<\/jats:styled-content> (rituximab, ifosfomide, carboplatin, etoposide) regimen with bendamustine (T(R)<jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>) via a multicentre phase I\/<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study for patients with relapsed or refractory diffuse large B cell lymphoma (<jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>) and classic Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>). Therapy consisted of 60\u2013120\u00a0mg\/m<jats:sup>2<\/jats:sup> per day bendamustine on days 1 and 2 in combination with carboplatin, etoposide and rituximab (only for <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20<jats:sup>+<\/jats:sup> lymphoma) used in the (R)<jats:styled-content style=\"fixed-case\">ICE<\/jats:styled-content> regimen for up to 2 cycles. The objectives were to define a maximally tolerated dose (<jats:styled-content style=\"fixed-case\">MTD<\/jats:styled-content>) of bendamustine, determine safety and toxicity, assess efficacy, and evaluate impact on stem cell collection. Forty\u2010eight patients were treated of which 71% had refractory disease. No dose\u2010limiting toxicities were observed. The recommended phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> dose of bendamustine was 120\u00a0mg\/m<jats:sup>2<\/jats:sup> per day on days 1 and 2. Response rates were 85% (70% complete response, <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>) in <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>, and 65% (40% <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>) in <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content>. Stem cell collection was successful in 30 of 32 patients. The most common non\u2010haematological toxicities \u2265grade 3 were febrile neutropenia (8%) and dehydration (8%). The T(R)<jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content> regimen safely yields high response rates, successfully mobilizes peripheral blood stem cells and compares favourably to <jats:styled-content style=\"fixed-case\">RICE<\/jats:styled-content>, offering an effective outpatient treatment option for patients with relapsed or refractory <jats:styled-content style=\"fixed-case\">DLBCL<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.15585","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T20:30:19Z","timestamp":1536957019000},"page":"601-607","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bendamustine with rituximab, etoposide and carboplatin (T(R)<scp>EC<\/scp>) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1\/2 clinical trial"],"prefix":"10.1111","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua E.","family":"Budde","sequence":"first","affiliation":[{"name":"Department of Hematology &amp; Hematopoietic Cell Transplantation City of Hope Duarte CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Martin","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Philip","sequence":"additional","affiliation":[{"name":"Department of Medicine Divisions of Medical Oncology and Hematology University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei R.","family":"Shustov","sequence":"additional","affiliation":[{"name":"Department of Medicine Divisions of Medical Oncology and Hematology University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted A.","family":"Gooley","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara L.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine Divisions of Medical Oncology and Hematology University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward N.","family":"Libby","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Group Health Permanente Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiarash","family":"Kojouri","sequence":"additional","affiliation":[{"name":"Skagit Valley Hospital Regional Center Mount Vernon WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Langerak","sequence":"additional","affiliation":[{"name":"St. Alphonsus Regional Medical Center Boise ID USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Roden","sequence":"additional","affiliation":[{"name":"Department of Medicine Divisions of Medical Oncology and Hematology University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Press","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-6834","authenticated-orcid":false,"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"},{"name":"Department of Medicine Divisions of Medical Oncology and Hematology University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"e_1_2_7_4_1","first-page":"e19517","article-title":"Cost\u2010comparison analysis of bendamustine, rituximab, etoposide and carboplatin (TREC) vs. RICE\/R\u2010DHAP in relapsed lymphoma","volume":"33","author":"Bodding\u2010Long A.M.","year":"2015","journal-title":"Journal of Clinical Oncology (ASCO Meeting Abstracts)"},{"key":"e_1_2_7_5_1","first-page":"1","article-title":"Bendamustine: mechanism of action and clinical data","volume":"9","author":"Cheson B.D.","year":"2011","journal-title":"Clinical Advances in Hematology & Oncology: H&O"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.7252"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_8_1","first-page":"485","article-title":"In vitro induction of apoptosis of neoplastic cells in low\u2010grade non\u2010Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine","volume":"86","author":"Chow K.U.","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0177"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.123"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood.V126.23.3982.3982","article-title":"Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma","volume":"126","author":"LaCasce A.S.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2011.03.003"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.616"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388058"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.3308"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2006.07.006"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4466"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.903"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15585","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T01:54:37Z","timestamp":1694742877000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,14]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/bjh.15585"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15585","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,14]]},"assertion":[{"value":"2018-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}